Wordt geladen...
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
BACKGROUND: Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. In this context, novel drug combinations are needed to increase its antitumor activity. In this work, we have evaluated the efficacy of...
Bewaard in:
| Gepubliceerd in: | J Exp Clin Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7980639/ https://ncbi.nlm.nih.gov/pubmed/33741018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01907-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|